Kohl's Corporation vs Revvity Inc — how do they compare? Kohl's Corporation trades at $20.35 (market cap $2.28B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 7.4× Kohl's Corporation's market cap, and Kohl's Corporation pays the higher dividend (2.49%). Which is the better fit depends on your goals — on Pluang, investors hold Kohl's Corporation for 48 Days and Revvity Inc for 12 Days on average.
| KSS | RVTY | |
|---|---|---|
Market Cap | $2.28B | $16.98B |
Volume | 4,960,280 | 1,456,900 |
Sector | Consumer Cyclical | Health |
52-Week High | $24.71 | $157.36 |
52-Week Low | $11.72 | $82.26 |
Typical Hold Time | 48 Days | 12 Days |
Enterprise Value | $7.88B | $19.30B |
Dividend Yield | 2.49% | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Kohl's (KSS) trades at $20.35, up 1.14% with a bullish technical outlook despite recent earnings beats. The stock shows attractive valuation metrics with P/E of 8.63 and P/S of 0.15, though revenue has declined from $19.4B in 2022 to $16.2B in 2025. Recent Q2 2026 earnings beat expectations with $1.28 EPS versus $0.58 expected, and the company raised full-year guidance amid merchandising improvements.
KSS presents a value opportunity with strong fundamentals but faces headwinds from 18 consecutive quarters of declining sales. Analyst consensus is mixed with 30% buy ratings and a $15.50 price target below current levels. The turnaround story depends on holiday execution and sales stabilization to sustain recent gains beyond tariff-related benefits.
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →